3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
3
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
21
Other solid neoplasm
4
Thoracic
3
Head & Neck
3
Gynecologic
3
Other hematologic neoplasm
2
Gastrointestinal
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
69
Docetaxel
50
Nivolumab
44
Prednisone
34
enzalutamide
30
Gemcitabine
26
Cyclophosphamide
22
Cisplatin
22
Paclitaxel
21
Radiotherapy
19
Carboplatin
19
Bevacizumab
19
Abiraterone Acetate
18
Ipilimumab
17
atezolizumab
14
Magnetic Resonance Spectroscopy
14
fludarabine
13
aldesleukin
13
Sunitinib
13
Interleukin-2
12
avelumab
11
Radiosurgery
11
Pluvicto
11
Filgrastim
11
Everolimus
11
gallium 68 PSMA-11
10
fludarabine phosphate
10
enfortumab vedotin
10
durvalumab
10
cemiplimab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
palbociclib
×
Genitourinary
×
Clear all
NCT05468697
2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
60 enrolled